SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors react to a significant stock price drop following a quarterly earnings report that showed revenue missing estimates and a continued full-year loss. The community is heavily divided between bears pointing to the company's high debt levels and poor leadership performance, and bulls who are buying the dip in anticipation of future cost reductions and a long-awaited strategic partnership with POSCO.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors monitor the early-stage commercial rollout of Yartemlea following recent FDA approval, with the community closely tracking initial shipment metrics and potential milestone payments from the Novo Nordisk partnership. Discussions are heavily focused on the stock's volatility around option expirations and the anticipation of upcoming regulatory milestones in Europe as catalysts for a potential revaluation.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy (LNG) is experiencing significant market interest driven by its strategic role in global energy supply, including recent long-term contracts and sustained demand from both data centers and international markets. Investors are actively debating the stock's potential for S&P 500 inclusion and its long-term positioning as a leader in natural gas exports.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging on massive volume as traders bet on its role as a key natural gas supplier amidst European energy supply concerns. The community is actively discussing the stock's low float and the potential for a sustained short squeeze as geopolitical tensions fuel broader interest in energy security plays.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as investors anticipate the official launch of its Super App and analyze its expanding ecosystem partnerships, including integrations with major payment infrastructure providers. The community remains deeply divided, with some users highlighting its long-term utility and potential for institutional adoption, while skeptics point to price stagnation and supply concerns as reasons for caution.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) is facing significant downward pressure as investors re-evaluate positions following historic volatility in precious metals and broader market corrections. Community sentiment is deeply divided, with many traders debating whether current price action represents a healthy consolidation phase for a long-term bull market or a deeper structural trend reversal fueled by rising production costs and fluctuating bond yields.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility as investors weigh the stock's elevated valuation against long-term growth prospects in the AI server and custom chip sectors. The community is actively debating the stock's technical stability, with many closely watching pivotal support levels while analyzing how potential macro-driven headwinds and upcoming earnings could impact the company's shift toward high-margin AI inference workloads.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is trending as investors rally behind its decentralized AI infrastructure, with significant excitement building around its upcoming supply-halving event. The community is actively discussing its potential to serve as the foundational "Bitcoin of AI" while sharing strategies on subnet delegation and long-term accumulation.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending following positive FDA acceptance for a priority review of its supplemental New Drug Application, which aims to expand the use of Imcivree to children as young as two years old. The community is actively discussing the stock's clinical milestones and the potential for acquisition interest as the company pushes to solidify its leadership in treating rare genetic obesity.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is generating significant community buzz as investors digest a recent positive regulatory determination from NOAA, which confirmed the company's application for deep-sea mining is in substantial compliance. While community members debate the timing of final permits and the upcoming TMCR spin-off listing, the consensus among long-term holders remains focused on the company's strategic role in securing a China-independent supply chain for critical battery metals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Satellos Bioscience to a "strong sell" rating in a research note on Saturday...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday. They set an "overweight" rating on the stock...

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle...

<ul class="summary-bullets"><li>MSLE stock&nbsp;was down about 2%&nbsp;in overnight trading heading into Tuesday.</li><li>The company completed a $57.2 million public offering to fund its lead drug, SAT-3247, and other research into muscle diseases.</li><li>Early data for SAT-3247 is expected in the second quarter of 2026, following encouraging adult safety results.</li></ul>Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday before ending the session more than 3% lower and dipping over 8% in after-hours trading.Investor sentiment took a hit after the company revealed it had completed an equity raise to fund its Duchenne muscular dystrophy (DMD) program and broader muscle disease research.&nbsp;<h2 class="st-heading-2">MSLE Wraps Up Equity Raise</h2>Satellos said it has completed its underwritten public offering, raising about $57.2 million before fees. The deal included roughly 5.2 million common shares, along with pre-funded warrants for some investors. The <a href="https://stocktwits.com/symbol/MSLE">shares of Satellos</a> were sold at $10.1 each. The stock is also listed on the Toronto Stock Exchange under the MSCL ticker.The company said the funds will mainly support research and development, with a focus on advancing SAT-3247, its lead drug candidate, into mid and late-stage clinical trials. Some of the money will also be used to explore additional muscle-related diseases and support early-stage research programs.Ahead of the Nasdaq listing, Satellos carried out a 1-for-12 share consolidation in late January. This reduced the total number of shares from about 185.5 million to roughly 15.5 million, helping the stock meet Nasdaq’s listing requirements.<h2 class="st-heading-2">How SAT-3247 Works</h2>SAT-3247 is an oral drug designed to help the body repair and regenerate muscle by targeting a protein called AAK1, which plays a role in muscle stem cell signaling. Unlike gene therapies, SAT-3247 does not depend on fixing the dystrophin gene, meaning it could potentially work for a wide range of Duchenne patients, regardless of their specific genetic mutation.In December, Satellos received FDA clearance and approvals from global regulators to begin a Phase 2 clinical study of SAT-3247 in 51 children with Duchenne. The study will test safety and measure changes in muscle strength and function. The company expects early trial results in the second quarter of 2026. Earlier studies in adults showed that the drug was well tolerated and associated with improvements in grip strength over a 28-day treatment period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Satellos Bioscience was ‘neutral’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/msle_ss_png_8d0bdc8b59.webp" alt="msle ss.png" width="973" height="142"><figcaption>MSLE sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure>One user said the company’s “Clinical results should be pretty stellar.”<stembedurl>https://stocktwits.com/bruceleeboy/message/644522213</stembedurl>Another user said, “It looks like all went well with the listing. Great work. Let’s see if we&nbsp; get something going this Spring.”<stembedurl>https://stocktwits.com/PennyScam/message/644421647</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday. (Photo credit: Getty Images)

Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours

SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.

Equity

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

MSLE
Satellos Bioscience Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MSLE News

MSLESatellos Bioscience Inc